Zoetis Inc. (NYSE:ZTS) Shares Purchased by Broadway Wealth Solutions Inc.

Broadway Wealth Solutions Inc. raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,746 shares of the company’s stock after purchasing an additional 73 shares during the period. Broadway Wealth Solutions Inc.’s holdings in Zoetis were worth $287,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC raised its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock worth $28,000 after buying an additional 166 shares in the last quarter. Navigoe LLC bought a new stake in shares of Zoetis during the 4th quarter worth about $30,000. Murphy & Mullick Capital Management Corp bought a new stake in shares of Zoetis during the 4th quarter worth about $44,000. Finally, Asset Planning Inc bought a new stake in shares of Zoetis during the 4th quarter worth about $58,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 0.9%

ZTS stock opened at $170.15 on Friday. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The company’s 50 day simple moving average is $157.41 and its 200-day simple moving average is $164.29. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The firm has a market capitalization of $75.75 billion, a P/E ratio of 31.11, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. The firm’s revenue was up 1.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Friday, July 18th. Zoetis’s payout ratio is presently 35.91%.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZTS. Stifel Nicolaus dropped their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a report on Monday, April 14th. Piper Sandler boosted their target price on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Monday, May 12th. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, UBS Group dropped their target price on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average target price of $212.75.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president now directly owns 15,129 shares of the company’s stock, valued at $2,571,930. The trade was a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,188 shares of company stock valued at $367,289. Corporate insiders own 0.18% of the company’s stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.